Long-acting APRETUDE was proven superior at reducing the risk of getting HIV vs once-daily Truvada
Randomized, double-blind, active-controlled clinical trials were used to make the results of the study less likely to be biased.
In these clinical trials, participants were randomly assigned to receive either APRETUDE + Truvada placebo or Truvada + APRETUDE placebo. Participants and investigators did not know which medicine they were receiving.
Approximately 8,000 participants
Included at-risk HIV-1—negative cisgender men, transgender women, and cisgender women
Study 1: 4,566 HIV-1—negative cisgender men and transgender women at risk for getting HIV
On APRETUDE: 12 out of 2,278 people became HIV positive
On Truvada: 39 out of 2,281 people became HIV positive
More people stayed HIV negative on APRETUDE vs Truvada during the study
In Study 1
50% of US participants identified as Black/African-American men
12% of global participants identified as transgender women
18% of US participants identified as Hispanic/Latino
Nearly two-thirds of participants were under 30. The median age was 26
Study 2: 3,224 HIV-1—negative cisgender women at risk for getting HIV
On APRETUDE: 3 of 1613 people became HIV positive
On Truvada: 36 out of 1610 people became HIV positive
In Study 2
3,224 women in Sub-Saharan Africa participated
Nearly half were younger than 25
APRETUDE is given every other month by a healthcare provider after initiation injections have been given 1 month apart for 2 consecutive months. Stay under a provider’s care while receiving APRETUDE. You must receive it as scheduled. If you will miss a scheduled injection by more than 7 days, call your provider right away.
